journal article·2023-05-08

Ce6/PTX2-NP/G@NHs Confer Radiosensitivity in Non-Small Cell Lung Cancer via Promotion of Apoptotic Body-Mediated Neighboring Effects

Jun Ma, Cuixia Wen, Meng Chen, Wei Zhang, Lifeng Wang, Haitao Yin

Publisher page

Abstract

This study fabricates a nanoparticle delivery system of gold nanoparticles–dextran nanoparticles loaded with hypoxia-activated paclitaxel dimeric prodrug nanoparticles (PTX 2 -NP) and photosensitizer chlorin e6/paclitaxel-nanoparticle/gold@ N -(2-hydroxypropyl) (Ce6/PTX 2 -NP/G@NHs) and analyzed the possible molecular mechanism for enhancing the radiosensitivity of non-small cell lung cancer (NSCLC). Ce6/PTX 2 -NP/G@NHs were prepared by a coupling reaction and dextran inclusion, followed by characterization using spectroscopy techniques. The cellular uptake and cytotoxicity of Ce6/PTX 2 -NP/G@NHs were analyzed. Radiosensitizing effects of the nanoparticles were evaluated by determining the malignant phenotypes and reactive oxygen species production of A549 cells and PI3K/AKT pathway-related proteins under 685 nm laser irradiation. A549 tumor-bearing nude mice were modeled to further confirm the radiosensitizing effect. Ce6/PTX 2 -NP/G@NHs were effectively internalized by A549 cells, producing cytotoxicity under laser irradiation. Ce6/PTX 2 -NP/G@NHs reduced cell viability, clonogenic potential, migration, and invasion along with reactive oxygen species (ROS) production while promoting apoptosis in A549 cells under laser irradiation. By inhibiting the PI3K/AKT pathway, Ce6/PTX 2 -NP/G@NHs increased the sensitivity of A549 cells to radiotherapy where apoptotic body (ApoBD)-mediated neighboring effects also played a key role. Ce6/PTX 2 -NP/G@NHs accumulated in tumor sites of nude mice and enhanced the radiosensitivity of NSCLC. Ce6/PTX 2 -NP/G@NHs showed no obvious toxicity or side effects in vivo . Collectively, the new Ce6/PTX 2 -NP/G@NHs nanoparticle delivery system can enhance the radiosensitivity of NSCLC via the promotion of ApoBD-mediated neighboring effects and inactivation of the PI3K/AKT pathway.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Radiation Therapy and Dosimetry · Extracellular vesicles in disease

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Radiotherapy Department, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210000, P. R. China

Radiotherapy Department, Xuzhou Central Hospital, No. 199, Jiefang South Road, Xuzhou 221000, P. R. China

Oncology Department, Nanjing 29 Drum Tower Hospital & The Affiliated Hospital of Nanjing University Medicine School, No. 321, Zhongshan Road, Nanjing 210000, P. R. China

Xuzhou Hospital of Traditional Chinese Medicine, Xuzhou 221000, P. R. China

Funding

Xuzhou Science and Technology Bureau · National Natural Science Foundation of China · Jiangsu Commission of Health · Medical leaders Foundation of Xuzhou City · Beijing Great Medical Public Welfare Foundation

References (34)

Show source-provided references
1. 10.3322/caac.2149210.3322/caac.21492 ↗
2. 10.1038/nature2518310.1038/nature25183 ↗
3. 10.1259/bjr.2019052410.1259/bjr.20190524 ↗
4. 10.1111/resp.1387010.1111/resp.13870 ↗
5. 10.1016/j.ijrobp.2021.08.04110.1016/j.ijrobp.2021.08.041 ↗
6. 10.1021/acsbiomaterials.1c0163110.1021/acsbiomaterials.1c01631 ↗
7. 10.1016/j.carbpol.2022.11983310.1016/j.carbpol.2022.119833 ↗
8. 10.1016/j.carpta.2021.10006710.1016/j.carpta.2021.100067 ↗
9. 10.1016/j.ijbiomac.2021.08.12410.1016/j.ijbiomac.2021.08.124 ↗
10. 10.3892/etm.2020.917810.3892/etm.2020.9178 ↗
11. 10.2147/IJN.S27290210.2147/IJN.S272902 ↗
12. 10.1080/21691401.2019.164515210.1080/21691401.2019.1645152 ↗
13. 10.1021/acsomega.1c0739310.1021/acsomega.1c07393 ↗
14. 10.1016/j.msec.2018.08.04510.1016/j.msec.2018.08.045 ↗
15. 10.1002/jmr.255210.1002/jmr.2552 ↗
16. 10.1016/j.apradiso.2020.10943910.1016/j.apradiso.2020.109439 ↗
17. 10.1016/j.jconrel.2020.02.01710.1016/j.jconrel.2020.02.017 ↗
18. 10.1016/j.addr.2017.02.00310.1016/j.addr.2017.02.003 ↗
19. 10.1016/j.lfs.2015.06.00610.1016/j.lfs.2015.06.006 ↗
20. 10.1016/j.biomaterials.2021.12106110.1016/j.biomaterials.2021.121061 ↗
21. 10.1016/j.saa.2020.11882310.1016/j.saa.2020.118823 ↗
22. 10.1016/j.omtn.2020.08.02110.1016/j.omtn.2020.08.021 ↗
23. 10.1016/j.apsb.2021.02.00110.1016/j.apsb.2021.02.001 ↗
24. 10.1002/anie.20200873210.1002/anie.202008732 ↗
25. 10.1080/20013078.2019.160878610.1080/20013078.2019.1608786 ↗
26. 10.1016/j.biomaterials.2020.11976110.1016/j.biomaterials.2020.119761 ↗
27. 10.1039/D0BM01452D10.1039/D0BM01452D ↗
28. 10.1039/D0TB02791J10.1039/D0TB02791J ↗
29. 10.1126/sciadv.abg088010.1126/sciadv.abg0880 ↗
30. 10.1038/cddis.2017.24210.1038/cddis.2017.242 ↗
31. 10.1093/jpp/rgab05610.1093/jpp/rgab056 ↗
32. 10.1038/s41392-020-0182-210.1038/s41392-020-0182-2 ↗
33. 10.1002/adma.20170339310.1002/adma.201703393 ↗
34. 10.1016/j.ijpharm.2019.11859510.1016/j.ijpharm.2019.118595 ↗